Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase II Clinical Trial of Myeloablative Conditioning Regimen With Fludarabine and Busulfan Plus 400 cGy Total Body Irradiation for Hematologic Malignancies

NCT00815568 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT00815568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00815568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase II Clinical Trial of Myeloablative Conditioning Regimen With Fludarabine and Busulfan Plus 400 cGy Total Body Irradiation for Hematologic Malignancies
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2008
Completion date
December 31, 2012
Enrollment
114 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

all, aml, cml, lymphoma, mds